65844-56-6

Usage

Uses

Used in Perfume Production:
Methyl 7-Methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate is used as a fragrance ingredient for its aromatic properties, contributing to the creation of various scents in perfumes.
Used as a Flavoring Agent:
Due to its aromatic nature, Methyl 7-Methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate is used as a flavoring agent in the food and beverage industry to enhance taste profiles.
Used in Organic Synthesis:
Methyl 7-Methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate serves as an intermediate in the synthesis of other organic compounds, facilitating the production of a range of chemical products.
Used in Pharmaceutical Development:
Methyl 7-Methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate's structural features suggest potential pharmaceutical applications, making Methyl 7-Methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate a candidate for further research and development in the pharmaceutical industry.

Upstream product

• 83781-48-0 <2-((trimethylsilyl)methyl)-5-methoxybenzyl>trimethylammonium iodide 
• 292638-85-8 acrylic acid methyl ester 
• 935740-89-9 [4-methoxy-2-{(trimethylsilyl)methyl}phenyl]methyl methyl carbonate 
• 52289-55-1 (4-methoxy-2-methylphenyl)methanol 
• 120072-87-9 methyl 1,2,3,4-tetrahydro-7-methoxy-1-oxo-2-naphthalenecarboxylate 
• 6836-19-7 7-Methoxy-1-tetralone 
• 76463-46-2 <2-<(trimethylsilyl)methyl>-5-methoxybenzyl>dimethylamine 
• 83781-94-6 (2-chloro-5-methoxybenzyl)dimethylamine 
• 935740-88-8 4-methoxy-2-[(trimethylsilyl)methyl]benzyl alcohol 

Downstream Products

• 31846-36-3 7-hydroxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 
• 1313494-65-3 4-([7-(([4-(aminomethyl)-3-(trifluoromethyl)phenyl]amino)carbonyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)-N-methylpyridine-2-carboxamide hydrochloride 
• 1274816-84-0 4-([7-(([4-cyano-3-(trifluoromethyl)phenyl]amino)carbonyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)-N-methylpyridine-2-carboxamide 
• 24833-31-6 1,2,3,4-tetrahydro-7-methoxy-2-naphthalenecarboxylic acid 

Relevant academic research and scientific papers

Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors

Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

Palladium-catalyzed formal [4+2] cycloaddtion of o-xylylenes with olefins

o-(Silylmethyl)benzylic carbonates reacted with various conjugated olefins in the presence of the palladium catalyst, which was generated in situ from Pd(η3-C3H5)Cp and 1,2-bis(diphenylphosphino)ethane (DPPE). The reaction

Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives.

This invention encompasses compounds of Formula 1 and the pharmaceutically acceptable salts thereof. wherein R1 represents alkyl having 2-6 carbon atoms; R2 represents methyl or ethyl; R3 represents alkyl having 1 to 5 carbon atoms; W represents (CH?)x where x is 2 to 7, alkylene having 2 to 7 carbon atoms, alkenylene having 3 to 7 carbon atoms, alkynylene having 3 to 7 carbon atoms, or cyclopentyl; R? represents hydrogen, alkyl having 2-5 carbon atoms, alkenyl having 2 to 5 carbon atoms, or alkynyl having 2 to 5 carbon atoms; Q represents oxygen or CH?; B represents CH?, C=O or CH-OH; R? represents hydrogen, alkyl having 1 to 6 carbon atoms, or R? and R? together optionally represent a carbon to carbon bond; or R? represents alkanoyl having 2 to 4 carbon atoms, carboxy, alkoxycarbonyl, or (CH?)y-CO?R? wherein y is 0 to 4 and R? is hydrogen or alkyl having 1 to 6 carbon atoms; and A represents-Z-CO?R? or-Z-COR?R1? wherein R? represents hydrogen or alkyl having 1 to 6 carbon atoms, R?, R1?, represent hydrogen, alkyl having 1 to 6 carbon atoms, or cycloalkyl having 3 to 6 carbon atoms or NR?R1? form a heterocyclic ring, and wherein Z is absent or represents straight or branched chain alkylene or alkenylene having up to 6 carbon atoms.These compounds are selective antagonists of leukotriene B?(LTB?) with little or no antagonism of leukotriene D? (LTD?) and are useful anti-inflammatory agents for treating inflammatory bowel disease, rheumatoid arthritis, gout and psoriasis.

Di-and tetrahydronapthyl anti-allergy agents

This invention relates to compounds of the formula: and the pharmaceutically acceptable salts thereof:, wherein R1 represents straight or branched chain alkyl having 2-4 carbon atoms;, wherein R2 represents hydrogen or straight or branched chain alkyl having 1-6 carbon atoms;, wherein R3 represents hydrogen or straight or branched chain alkyl having 1-3 carbon atoms;, wherein R4 and R10 are different and represent H or n-propyl;, wherein X represents an interger from 2 to 5;, wherein R5 is hydrogen, or acts with R7 to produce an additional carbon--carbon bond between C1 and C2;, wherein R6 represents hydrogen or -Z-COOR9, wherein Z is either absent or represents straight or branched chain alkyl or alkenyl having 1-5 carbon atoms; and R9 represents hydrogen, pharmaceutically acceptable cations, or straight or branched chain alkyl having 1-6 carbon atoms;, wherein R7 is hydrogen, or acts together with R5 to form an additional carbon-carbon bond between C1 and C2, or acts together with R8 to form when R8 is oxygen;, wherein R8 is hydrogen, -O-R11, or oxygen, such that when R8 is oxygen, R8 acts together with R7 to form and, wherein R11 is straight or branched chain alkyl having 1-4 carbon atoms. The di- and tetrahydronaphthyl compounds of this invention are pharmacologically active as leukotriene D4 (LTD4) antagonists and are useful as anti--inflammatory and anti-allergy agents.

Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives

This invention encompasses compounds of Formula 1 and the pharmaceutically acceptable salts thereof. STR1 wherein R1 represents alkyl having 2-6 carbon atoms; R2 represents methyl or ethyl; R3 represents alkyl having 1 to 5 carbon atoms; W represents (CH2)x where x is 2 to 7, alkylene having 2 to 7 carbon atoms, alkenylene having 3 to 7 carbon atoms, alkynylene having 3 to 7 carbon atoms, or cyclopentyl; R4 represents hydrogen, alkyl having 2-5 carbon atoms, alkenyl having 2 to 5 carbon atoms, or alkynyl having 2 to 5 carbon atoms; Q represents oxygen or CH2 ; B represents CH2, C=O or CH--OH; R5 represents hydrogen, alkyl having 1 to 6 carbon atoms, or R5 and R6 together optionally represent a carbon to carbon bond; or R5 represents alkanoyl having 2 to 4 carbon atoms, carboxy, alkoxycarbonyl, or (CH2)y--CO2 R8 wherein y is 0 to 4 and R8 is hydrogen or alkyl having 1 to 6 carbon atoms; and A represents --Z--CO2 R7 or --Z--COR9 R10 wherein R7 represents hydrogen or alkyl having 1 to 6 carbon atoms, R9, R10, represent hydrogen, alkyl having 1 to 6 carbon atoms, or cycloalkyl having 3 to 6 carbon atoms or NR9 R10 form a heterocyclic ring, and wherein Z is absent or represents straight or branched chain alkylene or alkenylene having up to 6 carbon atoms. These compounds are selective antagonists of leukotriene B4 (LTB4) with little or no antagonism of leukotriene D4 (LTD4) and are useful anti-inflammatory agents for treating inflammatory bowel disease, rheumatoid arthritis, gout and psoriasis.